Clinical Trials Logo
  1. Home
  2. Cancer
  3. NCT06134245
  4. Details
NCT06134245 Clinical Trial

HOme USability Evaluation

Cancer Clinical Trial

— HOUSE  

Official title:
HOme USability Evaluation

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06134245
Other study ID # IRAS ID: 336920
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 1, 2024
Est. completion date June 30, 2024

Study information
Verified date November 2023
Source Entia Ltd
Contact Hannah Rawlinson-Smith
Phone 020 3020 0030
Email hannah.rawlinson-smith@entia.co
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To validate the usability and safety of the Liberty Analyser.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 100
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Undergoing systemic anti-cancer therapy (SACT) - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2 at enrolment - Adequate English language skills (not requiring a translator) to participate in participant training and use the Entia Liberty analyser - Patients capable of providing written informed consent Exclusion Criteria: - History or current diagnosis of haematological malignancy - Patients with eyesight or hearing limitations or other disabilities that preclude the use of the Entia Liberty analyser or participation in training - Inadequate use and understanding of the English language, requiring a translator

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Entia Liberty
Home monitoring

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Entia Ltd

Outcome
Type Measure Description Time frame Safety issue
Primary The Entia Liberty Analyser is easy to use Users can easily carry out a test using the Entia Liberty Analyser Through study completion, 1 day
Primary The Entia Liberty Analyser is safe to use Results obtained using the Entia Liberty Analyser are valid and reliable Through study completion, 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients